New combo attack shrinks bulky tumors in early trial
NCT ID NCT06936748
First seen May 11, 2026 · Last updated May 21, 2026 · Updated 2 times
Summary
This study tests a two-step treatment for people with large, relapsed solid tumors that cannot be removed by surgery. First, a special type of radiation is given, followed by standard radiation combined with two immunotherapy drugs (iparomlimab and tuvonralimab). The goal is to see if this approach is safe and can shrink tumors. About 30 adults aged 18-75 with bulky tumors (over 6 cm) that have come back after prior treatment are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, 330006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.